There is 1 version of this bill. View text

Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries

Titles (2)

Short Titles

Short Titles - House of Representatives

Short Titles as Introduced

Lower Drug Costs Now Act of 2019

Official Titles

Official Titles - House of Representatives

Official Title as Introduced

To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.


Actions Overview (1)

Date
09/19/2019Introduced in House

All Actions (10)

Date
10/22/2019Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 24 - 17.
10/22/2019Committee Consideration and Mark-up Session Held.
10/17/2019Ordered to be Reported (Amended) by the Yeas and Nays: 27 - 21.
10/17/2019Committee Consideration and Mark-up Session Held.
09/25/2019Subcommittee Hearings Held.
Action By: House Energy and Commerce Subcommittee on Health
09/20/2019Referred to the Subcommittee on Health.
Action By: Committee on Energy and Commerce
09/19/2019Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Action By: House of Representatives
09/19/2019Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Action By: House of Representatives
09/19/2019Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Action By: House of Representatives
09/19/2019Introduced in House
Action By: House of Representatives

Cosponsors (99)

* = Original cosponsor
CosponsorDate Cosponsored
Rep. Neal, Richard E. [D-MA-1]* 09/19/2019
Rep. Scott, Robert C. "Bobby" [D-VA-3]* 09/19/2019
Rep. Larson, John B. [D-CT-1] 09/20/2019
Rep. Kuster, Ann M. [D-NH-2] 09/24/2019
Rep. DeGette, Diana [D-CO-1] 09/24/2019
Rep. Rush, Bobby L. [D-IL-1] 09/24/2019
Rep. Shalala, Donna E. [D-FL-27] 09/24/2019
Rep. Ryan, Tim [D-OH-13] 09/24/2019
Rep. Morelle, Joseph D. [D-NY-25] 09/24/2019
Rep. Sablan, Gregorio Kilili Camacho [D-MP-At Large] 09/24/2019
Rep. Case, Ed [D-HI-1] 09/24/2019
Rep. Engel, Eliot L. [D-NY-16] 09/25/2019
Rep. Castor, Kathy [D-FL-14] 09/25/2019
Rep. Frankel, Lois [D-FL-21] 09/25/2019
Rep. Evans, Dwight [D-PA-3] 09/25/2019
Rep. Courtney, Joe [D-CT-2] 09/25/2019
Rep. Norcross, Donald [D-NJ-1] 09/25/2019
Rep. Moore, Gwen [D-WI-4] 09/25/2019
Rep. Kildee, Daniel T. [D-MI-5] 09/25/2019
Rep. Norton, Eleanor Holmes [D-DC-At Large] 09/25/2019
Rep. McGovern, James P. [D-MA-2] 09/25/2019
Rep. Visclosky, Peter J. [D-IN-1] 09/26/2019
Rep. Carbajal, Salud O. [D-CA-24] 09/26/2019
Rep. Pappas, Chris [D-NH-1] 09/26/2019
Rep. Bonamici, Suzanne [D-OR-1] 09/26/2019
Rep. Hill, Katie [D-CA-25] 09/26/2019
Rep. Hayes, Jahana [D-CT-5] 10/01/2019
Rep. Cartwright, Matt [D-PA-8] 10/01/2019
Rep. McNerney, Jerry [D-CA-9] 10/01/2019
Rep. Blunt Rochester, Lisa [D-DE-At Large] 10/01/2019
Rep. Kim, Andy [D-NJ-3] 10/01/2019
Rep. Trone, David J. [D-MD-6] 10/01/2019
Rep. Allred, Colin Z. [D-TX-32] 10/01/2019
Rep. Rose, Max [D-NY-11] 10/01/2019
Rep. Thompson, Mike [D-CA-5] 10/01/2019
Rep. Meng, Grace [D-NY-6] 10/01/2019
Rep. Cohen, Steve [D-TN-9] 10/01/2019
Rep. Suozzi, Thomas R. [D-NY-3] 10/08/2019
Rep. Wild, Susan [D-PA-7] 10/08/2019
Rep. Eshoo, Anna G. [D-CA-18] 10/08/2019
Rep. Soto, Darren [D-FL-9] 10/08/2019
Rep. Horsford, Steven [D-NV-4] 10/08/2019
Rep. Vela, Filemon [D-TX-34] 10/08/2019
Rep. Beatty, Joyce [D-OH-3] 10/08/2019
Rep. Wasserman Schultz, Debbie [D-FL-23] 10/11/2019
Rep. Keating, William R. [D-MA-9] 10/11/2019
Rep. Golden, Jared F. [D-ME-2] 10/11/2019
Rep. Schiff, Adam B. [D-CA-28] 10/11/2019
Rep. Craig, Angie [D-MN-2] 10/11/2019
Rep. Welch, Peter [D-VT-At Large] 10/16/2019
Rep. Doyle, Michael F. [D-PA-18] 10/16/2019
Rep. Garcia, Sylvia R. [D-TX-29] 10/16/2019
Rep. Davis, Danny K. [D-IL-7] 10/16/2019
Rep. Ruiz, Raul [D-CA-36] 10/16/2019
Rep. Matsui, Doris O. [D-CA-6] 10/16/2019
Rep. Slotkin, Elissa [D-MI-8] 10/16/2019
Rep. Wilson, Frederica S. [D-FL-24] 10/16/2019
Rep. Loebsack, David [D-IA-2] 10/21/2019
Rep. Crist, Charlie [D-FL-13] 10/21/2019
Rep. Bustos, Cheri [D-IL-17] 10/21/2019
Rep. Mucarsel-Powell, Debbie [D-FL-26] 10/21/2019
Rep. Casten, Sean [D-IL-6] 10/21/2019
Rep. Schrier, Kim [D-WA-8] 10/21/2019
Rep. Cuellar, Henry [D-TX-28] 10/21/2019
Rep. Wexton, Jennifer [D-VA-10] 10/22/2019
Rep. Cleaver, Emanuel [D-MO-5] 10/22/2019
Rep. Schakowsky, Janice D. [D-IL-9] 10/22/2019
Rep. Sarbanes, John P. [D-MD-3] 10/22/2019
Rep. Maloney, Sean Patrick [D-NY-18] 10/28/2019
Rep. Lawson, Al, Jr. [D-FL-5] 10/28/2019
Rep. Phillips, Dean [D-MN-3] 10/28/2019
Rep. Schneider, Bradley Scott [D-IL-10] 10/28/2019
Rep. Meeks, Gregory W. [D-NY-5] 10/29/2019
Rep. Espaillat, Adriano [D-NY-13] 10/29/2019
Rep. Lynch, Stephen F. [D-MA-8] 10/29/2019
Rep. Higgins, Brian [D-NY-26] 10/30/2019
Rep. Langevin, James R. [D-RI-2] 10/30/2019
Rep. Chu, Judy [D-CA-27] 10/31/2019
Rep. Stevens, Haley M. [D-MI-11] 10/31/2019
Rep. Perlmutter, Ed [D-CO-7] 10/31/2019
Rep. Davids, Sharice [D-KS-3] 10/31/2019
Rep. Axne, Cynthia [D-IA-3] 11/01/2019
Rep. Hastings, Alcee L. [D-FL-20] 11/01/2019
Rep. Beyer, Donald S., Jr. [D-VA-8] 11/01/2019
Rep. Lowey, Nita M. [D-NY-17] 11/01/2019
Rep. McEachin, A. Donald [D-VA-4] 11/05/2019
Rep. Torres, Norma J. [D-CA-35] 11/08/2019
Rep. Payne, Donald M., Jr. [D-NJ-10] 11/08/2019
Rep. Scanlon, Mary Gay [D-PA-5] 11/08/2019
Rep. Deutch, Theodore E. [D-FL-22] 11/08/2019
Rep. Yarmuth, John A. [D-KY-3] 11/08/2019
Rep. Spanberger, Abigail Davis [D-VA-7] 11/08/2019
Rep. Jeffries, Hakeem S. [D-NY-8] 11/08/2019
Rep. McBath, Lucy [D-GA-6] 11/08/2019
Rep. Dingell, Debbie [D-MI-12] 11/12/2019
Rep. Finkenauer, Abby [D-IA-1] 11/12/2019
Rep. Garamendi, John [D-CA-3] 11/13/2019
Rep. McCollum, Betty [D-MN-4] 11/13/2019
Rep. Veasey, Marc A. [D-TX-33] 11/13/2019

Committees (3)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Reports
House Energy and Commerce09/19/2019 Referred to
House Energy and Commerce Subcommittee on Health09/20/2019 Referred to
09/25/2019 Hearings by
House Ways and Means09/19/2019 Referred to
10/22/2019 Markup by
House Education and Labor09/19/2019 Referred to
10/17/2019 Markup by

A related bill may be a companion measure, an identical bill, a procedurally-related measure, or one with text similarities. Bill relationships are identified by the House, the Senate, or CRS, and refer only to same-congress measures.


Subjects (1)


Latest Summary (1)

There is one summary for H.R.3. View summaries

Shown Here:
Introduced in House (09/19/2019)

Lower Drug Costs Now Act of 2019

This bill establishes several programs and requirements relating to the prices of prescription drugs.

In particular, the bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate prices for certain drugs (current law prohibits the CMS from doing so). Specifically, the CMS must negotiate maximum prices for (1) insulin products; and (2) at least 25 single source, brand name drugs that do not have generic competition and that are among the 125 drugs that account for the greatest national spending or the 125 drugs that account for the greatest spending under the Medicare prescription drug benefit and Medicare Advantage (MA). The negotiated prices must be offered under Medicare and MA, and may also be offered under private health insurance unless the insurer opts out.

The negotiated maximum price may not exceed (1) 120% of the average price in Australia, Canada, France, Germany, Japan, and the United Kingdom; or (2) if such information is not available, 85% of the U.S. average manufacturer price. Drug manufacturers that fail to comply with the bill's negotiation requirements are subject to civil and tax penalties.

The bill also makes a series of additional changes to Medicare prescription drug coverage and pricing. Among other things, the bill (1) requires drug manufacturers to issue rebates to the CMS for covered drugs that cost $100 or more and for which the average manufacturer price increases faster than inflation; and (2) reduces the annual out-of-pocket spending threshold, and eliminates beneficiary cost-sharing above this threshold, under the Medicare prescription drug benefit.